CIK 0001774857 · <br>Emerging growth company
Aardvark Therapeutics, Inc.
Sign in to watch- Ticker
- AARD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821606367
- Phone
- (858) 225-7696
- Business address
- 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $394,957
- in 1 filing, $395K under 10b5-1 plans
Net −$394,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-10 | Sun Nelson See Remarks | Sale 10b5-1 | −14,754 | $5.00 | $74K | 97,475 |
| 2026-08-14 | Chi Jeffrey Director | Grant or award · Stock Option (right to buy) | +44,964 | 44,964 | ||
| 2026-08-14 | Graf Susan E Director | Grant or award · Stock Option (right to buy) | +44,964 | 44,964 | ||
| 2026-08-14 | Baynes Roy D. Director | Grant or award · Stock Option (right to buy) | +44,964 | 44,964 | ||
| 2026-08-14 | Tong Victor Edward Jr Director | Grant or award · Stock Option (right to buy) | +44,964 | 44,964 | ||
| 2026-02-09 | Sun Nelson Chief Financial Officer | Grant or award · Stock option (right to buy) | −70,549 | 70,549 | ||
| 2026-02-09 | Lee Tien-Li Chief Executive Officer | Grant or award · Stock option (right to buy) | −203,851 | 203,851 | ||
| 2026-02-09 | Jaiman Manasi Chief Medical Officer | Grant or award · Stock option (right to buy) | −70,549 | 70,549 | ||
| 2025-12-11 | Sun Nelson Chief Financial Officer | Purchase | +3,000 | $14.40 | $43K | 108,484 |
| 2025-12-11 | Lee Tien-Li Chief Executive Officer | Purchase | +7,000 | $14.49 | $101K | 1,551,613 |
| 2025-10-15 | Lee Tien-Li Chief Executive Officer | Option exercise | +1,229 | $4.24 | $5K | 1,544,613 |
| 2025-10-15 | Lee Tien-Li Chief Executive Officer | Option exercise · Stock option (right to buy) | −1,229 | 40,566 | ||
| 2025-10-15 | Jones Bryan Chief Operating Officer | Option exercise | +1,250 | $4.24 | $5K | 1,250 |
| 2025-10-15 | Jones Bryan Chief Operating Officer | Option exercise · Stock option (right to buy) | −1,250 | 40,052 | ||
| 2025-09-15 | Lee Tien-Li Chief Executive Officer | Purchase | +6,500 | $9.51 | $62K | 1,539,884 |
| 2025-09-15 | Lee Tien-Li Chief Executive Officer | Purchase | +3,500 | $9.94 | $35K | 1,543,384 |
| 2025-09-12 | Lee Tien-Li Chief Executive Officer | Purchase | +5,000 | $8.50 | $43K | 1,533,384 |
| 2025-09-11 | Lee Tien-Li Chief Executive Officer | Purchase | +6,000 | $7.82 | $47K | 1,528,384 |
| 2025-09-10 | Lee Tien-Li Chief Executive Officer | Purchase | +9,000 | $7.91 | $71K | 1,522,384 |
| 2025-09-09 | Sun Nelson Chief Financial Officer | Purchase | +6,000 | $8.07 | $48K | 105,484 |
Page 2 of 4 · 71 trades